<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infection</z:e> remains the most common cause of infectious <z:hpo ids='HP_0011420'>death</z:hpo> in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In this open-label, randomized study, we compared the efficacy and safety of caspofungin with that of intravenous <z:chebi fb="0" ids="6076">itraconazole</z:chebi> for antifungal prophylaxis in patients undergoing induction chemotherapy for <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Of 200 patients, 192 were evaluable for efficacy (86 for <z:chebi fb="0" ids="6076">itraconazole</z:chebi>, 106 for caspofungin) </plain></SENT>
<SENT sid="3" pm="."><plain>Duration of prophylaxis (median, 21 days [range, 1 to 38 days]), demographics, and prognostic factors were similar in both groups </plain></SENT>
<SENT sid="4" pm="."><plain>Ninety-nine patients completed antifungal prophylaxis without developing <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infection</z:e> (44 [51%] with <z:chebi fb="0" ids="6076">itraconazole</z:chebi>, 55 [52%] with caspofungin) </plain></SENT>
<SENT sid="5" pm="."><plain>Twelve patients developed documented invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e>, five in the <z:chebi fb="0" ids="6076">itraconazole</z:chebi> group (four with <z:e sem="disease" ids="C0877445" disease_type="Disease or Syndrome" abbrv="">candidemia</z:e> and one with Aspergillus <z:hpo ids='HP_0002090'>pneumonia</z:hpo>), and seven in the caspofungin group (two with <z:e sem="disease" ids="C0877445" disease_type="Disease or Syndrome" abbrv="">candidemia</z:e>, two with disseminated trichosporon species, two with Aspergillus <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, and one with disseminated Fusarium spp) </plain></SENT>
<SENT sid="6" pm="."><plain>Two patients in the <z:chebi fb="0" ids="6076">itraconazole</z:chebi> group and four in the caspofungin group died of <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infection</z:e> (P = 0.57) </plain></SENT>
<SENT sid="7" pm="."><plain>Grade 3 to 4 adverse event rates were comparable between groups; the most common event in both was reversible <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>No evidence of cardiovascular toxicity from intravenous <z:chebi fb="0" ids="6076">itraconazole</z:chebi> was noted among patients older than 60 </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, intravenous <z:chebi fb="0" ids="6076">itraconazole</z:chebi> and caspofungin provided similar protection against invasive <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infection</z:e> during induction chemotherapy, and both drugs were well tolerated </plain></SENT>
</text></document>